Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma.~* Status of refractory to or relapsed from at least one prior bortezomib-containing regimen.~* Progressive disease.~* Age \>= 18 years.~* Karnofsky performance status \>= 60%~* Acceptable liver function:~  * Bilirubin =\< 1.5 x ULN (upper limit of normal)~ * Aspartate transaminase (AST) and alanine transaminase (ALT) =\< 3 x ULN~* Acceptable hematologic status:~  * Absolute Neutrophil Count (ANC) \>= 1.5 x 109/L~ * Platelet count \>= 100 x 109/L~ * Hemoglobin \>= 9 g/dL~ * Coagulation status PT-INR/PTT =\< 1.5 x ULN or in the therapeutic range if on anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized ratio / prothrombin time)~ * Serum potassium within normal range.~* Estimated life expectancy greater than 3 months.~* Signed, written IRB (institutional Review Board)-approved informed consent.~Exclusion Criteria:~* Non-secretory multiple myeloma or symptomatic amyloidosis.~* Hypersensitivity to bortezomib, boron, or mannitol.~* Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or immunotherapy, except if disease is rapidly progressing.~* Less than 4 weeks since prior use of other investigational agents.~* Serious concomitant systemic disorders (e.g. active infection).~* Significant cardiovascular disease.~* Marked baseline prolongation of QT/QTc (corrected QT interval)interval.~* Central nervous system disorders requiring neuroleptics / anti-convulsants.~* Peripheral sensory neuropathy of ≥ Grade 2~* Renal insufficiency defined as a creatinine clearance of \< 30 ml/min.~* Non-willingness to use effective contraceptive methods for patients of child-bearing age / potential.~* Pregnant or breast-feeding women.~* Known HIV positivity.~* Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase) inhibitor.~* Altered mental status which precludes an understanding of the Informed Consent Document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).